Pandemic H1N1 vaccine requires the use of an adjuvant to protect against challenge in naïve ferrets
In the context of an A/H1N1 influenza pandemic situation, this study demonstrates that heterologous vaccination with an AS03-adjuvanted 2008/2009 seasonal trivalent and pandemic H5N1 monovalent split vaccine conferred partial protection in influenza-naïve ferrets after challenge with the influenza pandemic H1N1 A/The Netherlands/602/09 virus. Further, unlike saline control and non-adjuvanted vaccine, it was shown that immunization of naïve ferrets with an AS03-adjuvanted pandemic H1N1 A/California/7/09 influenza split vaccine induced increased antibody response and enhanced protection against the challenge strain, including significant reduction in viral shedding in the upper respiratory tract and reduced lung pathology post-challenge. These results show the need for vaccination with the adjuvanted vaccine to fully protect against viral replication and influenza disease in unprimed ferrets.
|Keywords||2009 H1N1 influenza, Netherlands, United States, adjuvant therapy, alpha tocopherol, animal experiment, animal model, antibody response, article, controlled study, drug potentiation, emulsion, female, ferret, influenza vaccination, influenza vaccine, male, nonhuman, priority journal, upper respiratory tract infection, virus replication, virus shedding|
|Persistent URL||dx.doi.org/10.1016/j.vaccine.2010.12.125, hdl.handle.net/1765/23376|
Baras, B., de Waal, L., Stittelaar, K.J., Jacob, V., Giannini, S., Veldhuis Kroeze, E.J.B., … Osterhaus, A.D.M.E.. (2011). Pandemic H1N1 vaccine requires the use of an adjuvant to protect against challenge in naïve ferrets. Vaccine, 29(11), 2120–2126. doi:10.1016/j.vaccine.2010.12.125